Dr. Charles Glueck MD

Director of Cholesterol Center, Jewish Hospital

GLG News by Dr. Charles Glueck MD, Director of Cholesterol Center

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Study: Lab test can prevent severe blood clots in testosterone patients

September 30, 2011

A recent study finds that a blood test can prevent disastrous blood clots in men receiving testosterone therapy.

CETP INHIBITORS- A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC

March 6, 2007

Analysis of:CETP INHIBITORS: A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC | mediaroom.pfizer.com

By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably, with torcetrapib this sequence of events seemed to occur. Our concern is that this is a class effect and that CETP inhibitors are not a fruitful area for further drug development.

Page : 11 to 2 of 2

Subscribe to Updates

By RSS